Lyell Immunopharma (LYEL) Total Non-Current Liabilities (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Total Non-Current Liabilities data on file, last reported at $76.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 15.2% year-over-year to $76.4 million; the trailing twelve-month figure through Mar 2026 stood at $76.4 million (down 15.2% YoY), and the FY2025 full-year result was $91.3 million, down 12.84% from the prior year.
• Total Non-Current Liabilities eased to $76.4 million in Q1 2026, from $91.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $186.4 million in Q1 2022 to a low of $76.2 million in Q3 2025.
• A 5-year average of $102.2 million and a median of $91.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities tumbled 50.31% in 2023 and increased 14.62% in 2024, its largest moves.
• Tracing LYEL's Total Non-Current Liabilities over 5 years: stood at $100.2 million in 2022, then dropped by 8.77% to $91.4 million in 2023, then rose by 14.62% to $104.8 million in 2024, then slipped by 12.84% to $91.3 million in 2025, then decreased by 16.31% to $76.4 million in 2026.
• Business Quant data shows LYEL's Total Non-Current Liabilities at $76.4 million in Q1 2026, $91.3 million in Q4 2025, and $76.2 million in Q3 2025.